Primary progressive ms and steroid treatment

According to Genentech, Ocrevus was the first investigational medicine to show such positive results in patients with both primary progressive and relapsing forms of MS. The company submitted data from all three studies to regulatory authorities in mid-2016, which paved the way for marketing and commercialization of Ocrevus to treat RMS and PPMS. On June 28, 2016, Genentech announced that the company’s Biologics License Application for Ocrevus had been accepted for FDA review, and that the therapy was granted Priority Review, accelerating the review process. All those efforts resulted in the FDA’s decision to approved Ocrevus on March 28, 2017.

The content published on this website was not written by medical professionals and should not, at any point, be mistaken for medical advice. The information on this site is intended for educational purposes only and should never interfere with a patient/site visitor and his or her healthcare provider. In addition, viewing the content on this website, requesting additional information, or transmitting information through a contact form should never be considered the formation of an attorney-client relationship. You are not considered a client until you have signed a retainer agreement and your case has been accepted by us. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Primary progressive ms and steroid treatment

primary progressive ms and steroid treatment

Media:

primary progressive ms and steroid treatmentprimary progressive ms and steroid treatmentprimary progressive ms and steroid treatmentprimary progressive ms and steroid treatmentprimary progressive ms and steroid treatment

http://buy-steroids.org